Atavistik Bio Raises $40M in Series B Extension Funding to Advance Allosteric Drug Platform

Atavistik Bio operates in the lane where biology itself becomes the lever for the future, and the market just doubled down on that bet. The Cambridge-based biotech closed a $40M Series B extension, pushing the total Series B to $160M and total capital raised to at least $220M since its $60M Series A in 2021. RA Capital Management led the extension, joining a table that already includes Nextech Invest, The Column Group, Lux Capital, and Regeneron Ventures. When that many sharp minds keep writing checks, you know the science is making noise in the room.

Congratulations to CEO Bryan E. Stuart and President and CSO Marion Dorsch, PhD for steering this ship through the kind of waters where science meets conviction. Also credit to CMO Susan Pandya, M.D., who joined the leadership ranks as the company moved deeper into clinical territory. This crew is building more than a pipeline. They are building a system for discovering precision allosteric therapies that reach parts of biology most drugs never touch.

The engine behind it all is the AMPS platform, short for Atavistik Metabolite Protein Screening. The concept sounds simple until you realize what it unlocks. Instead of hammering proteins with blunt force inhibition, the platform finds cryptic allosteric pockets and tunes them like a musician adjusting pitch. The result is selective small molecule modulators designed to influence disease pathways with far more precision. Less noise. More signal. In biotech terms that can mean better tolerability and the ability to treat diseases where older approaches struggled to land a clean hit.

That approach is already taking shape in the clinic. ATV 1601, an oral AKT1 selective allosteric inhibitor, is moving forward for hereditary hemorrhagic telangiectasia, a severe inherited bleeding disorder affecting more than 1.6M people worldwide with no approved therapies. Alongside that program sits a JAK2 V617F mutant selective inhibitor aimed at myeloproliferative neoplasms. The strategy is elegant. Target the mutation, preserve the normal biology, and give patients a therapy that is designed to work with the body rather than bulldoze through it.

There is a lesson here for founders and operators watching from the sidelines. Capital does not chase hype for long in biotech. It follows platforms that repeatedly open new doors. Atavistik Bio built a discovery engine capable of revealing hidden biology, then stacked a clinical pipeline on top of it. Investors saw a machine, not just a molecule. And when venture capital believes the machine keeps producing, the checks tend to keep coming.